These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25577866)

  • 1. [A review of the expression and activity of drug metabolism enzymes in tumorous cells].
    Xiao WJ; Wang GJ; A JY
    Yao Xue Xue Bao; 2014 Oct; 49(10):1377-86. PubMed ID: 25577866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-metabolizing enzymes: role in drug resistance in cancer.
    Kaur G; Gupta SK; Singh P; Ali V; Kumar V; Verma M
    Clin Transl Oncol; 2020 Oct; 22(10):1667-1680. PubMed ID: 32170639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy.
    Feng S; Li A; Zheng YC; Liu HM
    Curr Drug Metab; 2020; 21(1):67-76. PubMed ID: 31902352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism by tumours: its nature, relevance and therapeutic implications.
    Michael M; Doherty MM
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):783-803. PubMed ID: 18028025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review.
    Raju B; Choudhary S; Narendra G; Verma H; Silakari O
    Drug Metab Rev; 2021 Feb; 53(1):45-75. PubMed ID: 33535824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
    Hattinger CM; Serra M
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo.
    Lorenzi PL; Landowski CP; Song X; Borysko KZ; Breitenbach JM; Kim JS; Hilfinger JM; Townsend LB; Drach JC; Amidon GL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):883-90. PubMed ID: 15901797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
    Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
    Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumoral drug metabolism: overview and its implications for cancer therapy.
    Michael M; Doherty MM
    J Clin Oncol; 2005 Jan; 23(1):205-29. PubMed ID: 15625375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
    Ozawa S
    Rinsho Byori; 2003 Feb; 51(2):168-73. PubMed ID: 12690635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-activated prodrug (TAP)-conjugated nanoparticles with cleavable domains for safe doxorubicin delivery.
    Guarnieri D; Biondi M; Yu H; Belli V; Falanga AP; Cantisani M; Galdiero S; Netti PA
    Biotechnol Bioeng; 2015 Mar; 112(3):601-11. PubMed ID: 25220931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins.
    He X; Lu W; Jiang X; Cai J; Zhang X; Ding J
    Bioorg Med Chem; 2004 Aug; 12(15):4003-8. PubMed ID: 15246077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
    Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
    Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828.
    Binderup E; Björkling F; Hjarnaa PV; Latini S; Baltzer B; Carlsen M; Binderup L
    Bioorg Med Chem Lett; 2005 May; 15(10):2491-4. PubMed ID: 15863303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.